Northwestern University Lead Academic Participating Site

项目摘要/摘要 西北大学罗伯特·H·卢里综合癌症中心(LCC)有很长的历史 1973年以来以经社理事会成员身份参加NCTN的历史。目前，LCC 基础设施支持通过经社理事会参与临床试验和辅助研究- ACRIN、SWOG、Alliance、NRG和COG。公认的应计、参与和高水平 在数据质量方面，LCC已被NCTN领导层选中参加High 在2015年、2016年和2017年实施现场计划(HPSI)，以支持我们的基础设施和 允许继续参与NCTN试验。Lurie癌症中心对NCTN的总体收益 3/1/14-8/31/17期间的研究为400篇，其中383篇为干预性试验。 此外，LCC成员积极参与NCTN活动的领导。从14年3月1日 和8/31/16，LCC成员担任网络小组委员会和小组委员会 委员(74人)、委员会和小组委员会主席和联席主席(19人)、研究会主席和联席主席 (22)，以及各NCI指导委员会或特别工作组的成员(10)。此外， 大量网络小组出版物(65份)和摘要(70份)由作者或合著 调查人员仅在过去三年就进一步表明了我们在以下方面的领导作用 NCTN。 通过展示重大科学成就和新倡议，最近 招聘有成就的高级教员和富有成效的初级教员，全面和 监督癌症相关临床试验的综合基础设施，包括建立 NCTN监督委员会，强调对初级教师的指导，大量财政 对NCTN活动的支持以及经验丰富和富有成效的领导层 LCC在NCTN内持续活跃，证明了它有治理能力， 组织能力和承诺，以及高级管理人员的一般专业知识 领导团队支持此LAPS应用程序。

PROJECT SUMMARY/ABSTRACT The Robert H. Lurie Comprehensive Cancer Center of Northwestern University (LCC) has a long history of NCTN participation with ECOG membership since 1973. Currently, the LCC infrastructure supports participation in clinical trials and ancillary studies through the ECOG- ACRIN, SWOG, Alliance, NRG and COG. Recognized for accrual, participation, and high-level of data quality, the LCC has been selected by the NCTN leadership to participate in the High Performing Site Initiative (HPSI) in 2015, 2016 and 2017 to support our infrastructure and to enable continued participation in NCTN trials. The Lurie Cancer Center's overall accrual to NCTN studies during 3/1/14 - 8/31/17 was 400, 383 of which were accrued to Interventional trials. In addition, LCC members are heavily involved in the leadership of NCTN activities. From 3/1/14 and 8/31/16, LCC members have served as Network Group committee and subcommittee members (74), committee and subcommittee chairs and co-chairs (19), study chairs and co-chairs (22), and members of various NCI Steering Committees or Task Forces (10). In addition, the extensive number of Network Group publications (65) and abstracts (70) authored or co-authored by the investigators during the last 3 years alone further demonstrates our leadership role within the NCTN. Through demonstration of significant scientific accomplishments and new initiatives, recent recruitment of accomplished senior faculty and productive junior faculty, comprehensive and integrated infrastructure for oversight of cancer-related clinical trials including the establishment of a NCTN Oversight Committee, emphasis on mentoring of junior faculty, significant financial support of NCTN activities and a highly experienced and productive leadership which has been continuously active within the NCTN, the LCC has proved that it has the governance, organizational capabilities and commitment, as well as the general expertise of the senior leadership team to support this LAPS application.